<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39059">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597907</url>
  </required_header>
  <id_info>
    <org_study_id>KNUH 2014-05-016</org_study_id>
    <nct_id>NCT02597907</nct_id>
  </id_info>
  <brief_title>Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the antiemetic efficacy of aprepitant plus
      palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic
      cholecystectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of postoperative nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>The incidence of postoperative nausea and vomiting during 24 hours postoperatively</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>aprepitant plus palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aprepitant 80 mg palonosetron 0.075 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aprepitant plus ramosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aprepitant 80 mg ramosetron 0.3 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>aprepitant 80 mg is given to all patients before surgery</description>
    <arm_group_label>aprepitant plus palonosetron</arm_group_label>
    <arm_group_label>aprepitant plus ramosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron</intervention_name>
    <description>palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia</description>
    <arm_group_label>aprepitant plus palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia</description>
    <arm_group_label>aprepitant plus ramosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non smoking, female patients, scheduled for laparoscopic cholecystectomy

        Exclusion Criteria:

          -  Patients with gastrointestinal disorder,

          -  Patients with allergies to any study medication,

          -  Patients who had received any sedatives, opioid, steroid or antiemetics within 24 h
             before surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 4, 2015</lastchanged_date>
  <firstreceived_date>October 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Younghoon Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
